MCID: OVR040
MIFTS: 27

Ovarian Clear Cell Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Clear Cell Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Clear Cell Cystadenocarcinoma:

Name: Ovarian Clear Cell Cystadenocarcinoma 12 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:7438
NCIt 49 C7980
UMLS 71 C0279667

Summaries for Ovarian Clear Cell Cystadenocarcinoma

Disease Ontology : 12 An ovarian cystadenocarcinoma that is characterized by the presence of cells with clear cytoplasm.

MalaCards based summary : Ovarian Clear Cell Cystadenocarcinoma is related to linitis plastica and fallopian tube endometrioid adenocarcinoma. An important gene associated with Ovarian Clear Cell Cystadenocarcinoma is APOLD1 (Apolipoprotein L Domain Containing 1), and among its related pathways/superpathways are PEDF Induced Signaling and PI3K-Akt signaling pathway. The drugs Cisplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and bone marrow, and related phenotype is integument.

Related Diseases for Ovarian Clear Cell Cystadenocarcinoma

Diseases related to Ovarian Clear Cell Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
# Related Disease Score Top Affiliating Genes
1 linitis plastica 10.0 ERBB2 APOLD1
2 fallopian tube endometrioid adenocarcinoma 10.0 ERBB2 APOLD1
3 rectum adenocarcinoma 10.0 ERBB2 APOLD1
4 iritis 9.9 TNFRSF1B EPO
5 ascending colon cancer 9.8 CSF3 APOLD1
6 pneumocystosis 9.7 TNFRSF1B CSF3
7 pyoderma 9.7 TNFRSF1B CSF3
8 female breast cancer 9.7 ERBB2 CSF3
9 acute radiation syndrome 9.7 EPO CSF3
10 retinitis pigmentosa and erythrocytic microcytosis 9.7 EPO CSF3
11 refractory anemia 9.7 EPO CSF3
12 hair disease 9.7 ERBB2 CSF3
13 poems syndrome 9.7 EPO CSF3
14 hypersplenism 9.7 EPO CSF3
15 acquired immunodeficiency syndrome 9.6 TNFRSF1B EPO
16 hemoglobinuria 9.6 EPO CSF3
17 blood coagulation disease 9.6 EPO CSF3
18 fallopian tube serous adenocarcinoma 9.6 TNFRSF1B EPO APOLD1
19 aspergillosis 9.6 TNFRSF1B CSF3
20 pulmonary edema 9.6 EPO CSF3
21 sickle cell anemia 9.6 EPO CSF3
22 thrombocytosis 9.5 EPO CSF3
23 bone marrow cancer 9.5 EPO CSF3
24 blood platelet disease 9.4 EPO CSF3
25 exanthem 9.4 TNFRSF1B ERBB2 CSF3
26 pancytopenia 9.3 EPO CSF3
27 miliary tuberculosis 9.3 TNFRSF1B EPO CSF3
28 myeloma, multiple 9.2 ERBB2 EPO CSF3
29 leukemia, chronic myeloid 9.2 ERBB2 EPO CSF3
30 thrombocytopenia 9.2 ERBB2 EPO CSF3
31 polycythemia vera 9.2 EPO CSF3
32 leukemia, acute myeloid 9.1 ERBB2 EPO CSF3
33 myelodysplastic syndrome 8.9 TNFRSF1B ERBB2 EPO CSF3
34 ovarian clear cell malignant adenofibroma 8.6 TNFRSF1B ERBB2 EPO CSF3 APOLD1
35 mixed epithelial tumor of ovary 8.6 TNFRSF1B ERBB2 EPO CSF3 APOLD1
36 fallopian tube transitional cell carcinoma 8.6 TNFRSF1B ERBB2 EPO CSF3 APOLD1
37 fallopian tube mucinous adenocarcinoma 8.6 TNFRSF1B ERBB2 EPO CSF3 APOLD1

Graphical network of the top 20 diseases related to Ovarian Clear Cell Cystadenocarcinoma:



Diseases related to Ovarian Clear Cell Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Cystadenocarcinoma

MGI Mouse Phenotypes related to Ovarian Clear Cell Cystadenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 8.92 CSF3 EPO ERBB2 TNFRSF1B

Drugs & Therapeutics for Ovarian Clear Cell Cystadenocarcinoma

Drugs for Ovarian Clear Cell Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
4
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7 Angiogenesis Inhibitors Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9 Albumin-Bound Paclitaxel Phase 2, Phase 3
10 Antimitotic Agents Phase 2, Phase 3
11 Topoisomerase Inhibitors Phase 3
12 Immunosuppressive Agents Phase 3
13 Immunologic Factors Phase 3
14 Alkylating Agents Phase 3
15 Analgesics Phase 3
16 Antirheumatic Agents Phase 3
17
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Lenograstim Approved, Investigational Phase 2 135968-09-1
20
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
21
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
22
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
23
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
24
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
25 topoisomerase I inhibitors Phase 2
26 Anti-Bacterial Agents Phase 2
27 Antibiotics, Antitubercular Phase 2
28
Liposomal doxorubicin Phase 2 31703
29 Protein Kinase Inhibitors Phase 1, Phase 2
30
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
31 Anti-Infective Agents Phase 2
32 Antifungal Agents Phase 2
33 Antimetabolites Phase 2
34
Melphalan Approved Phase 1 148-82-3 4053 460612
35
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
36
Pancrelipase Approved, Investigational Phase 1 53608-75-6
37
Iodine Approved, Investigational Phase 1 7553-56-2 807
38
Etoposide Approved Phase 1 33419-42-0 36462
39
Veliparib Investigational Phase 1 912444-00-9 11960529
40 Antibodies, Monoclonal Phase 1
41 Antibodies Phase 1
42 Immunoglobulins Phase 1
43 Immunotoxins Phase 1
44 Adjuvants, Immunologic Phase 1
45 Interleukin-12 Phase 1
46 Gastrointestinal Agents Phase 1
47 Liver Extracts Phase 1
48 pancreatin Phase 1
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
50 Immunoglobulin G Phase 1

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
3 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
4 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
7 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
8 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
9 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
10 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
11 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
12 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
13 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
14 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
15 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
16 A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy Completed NCT00993655 Phase 2 carboplatin;cisplatin;paclitaxel
17 A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum Terminated NCT00354601 Phase 2 capecitabine;docetaxel
18 A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
19 A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
20 A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
21 A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer Completed NCT00002977 Phase 1 melphalan;thiotepa
22 A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
23 A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
24 Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing Completed NCT00066651 Phase 1
25 A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
26 A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
27 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
28 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
29 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
30 A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
31 Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Completed NCT00408590 Phase 1
32 A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
33 Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis Unknown status NCT00238342
34 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Unknown status NCT00897039
35 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514

Search NIH Clinical Center for Ovarian Clear Cell Cystadenocarcinoma

Genetic Tests for Ovarian Clear Cell Cystadenocarcinoma

Anatomical Context for Ovarian Clear Cell Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Clear Cell Cystadenocarcinoma:

40
Ovary, T Cells, Bone Marrow, Bone, Liver, Testes, Endothelial

Publications for Ovarian Clear Cell Cystadenocarcinoma

Variations for Ovarian Clear Cell Cystadenocarcinoma

Expression for Ovarian Clear Cell Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Cystadenocarcinoma.

Pathways for Ovarian Clear Cell Cystadenocarcinoma

Pathways related to Ovarian Clear Cell Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 TNFRSF1B ERBB2 EPO CSF3
2
Show member pathways
12.33 ERBB2 EPO CSF3
3 11.43 EPO CSF3
4 11.29 ERBB2 EPO
5 11.15 EPO CSF3
6 10.65 TNFRSF1B CSF3
7 10.3 EPO CSF3

GO Terms for Ovarian Clear Cell Cystadenocarcinoma

Biological processes related to Ovarian Clear Cell Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.33 ERBB2 EPO CSF3
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 EPO CSF3
3 cellular response to growth factor stimulus GO:0071363 8.96 TNFRSF1B ERBB2
4 negative regulation of neuron death GO:1901215 8.8 TNFRSF1B EPO CSF3

Sources for Ovarian Clear Cell Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....